Physician profile
David B Levy
NPI 1437101714
$12,390.33
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,951 · 2020: $2,089 · 2021: $2,871 · 2022: $2,242 · 2023: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.77 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,658.74 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $1,450.41 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,428.55 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,092.71 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $853.68 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $768.98 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $717.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $505.05 | 2019-2023 | Steglatro, Dificid, Belsomra |
| Janssen Pharmaceuticals, INC | $463.18 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $368.71 | 2019-2022 | |
| Astellas Pharma US INC | $309.33 | 2019-2023 | Veozah |
| Preventric Diagnostics, INC. | $294.79 | 2021-2022 | |
| Amarin Pharma, INC. | $257.97 | 2019-2020 | |
| Abbvie INC. | $255.77 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $203.39 | 2019-2023 | Eliquis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.